In the latest session, Amneal Pharmaceuticals Inc (NASDAQ: AMRX) closed at $5.31 down -0.56% from its previous closing price of $5.34. In other words, the price has decreased by -$0.03 from its previous closing price. On the day, 1134812 shares were traded. AMRX stock price reached its highest trading level at $5.39 during the session, while it also had its lowest trading level at $5.21.
Ratios:
For a deeper understanding of Amneal Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 17.02 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.49. For the most recent quarter (mrq), Quick Ratio is recorded 1.16 and its Current Ratio is at 1.91. In the meantime, Its Debt-to-Equity ratio is 8.48 whereas as Long-Term Debt/Eq ratio is at 8.11.
On March 08, 2021, Goldman Upgraded its rating to Buy which previously was Sell and also upped its target price recommendation from $4 to $6.50.
Guggenheim Upgraded its Neutral to Buy on December 14, 2020, while the target price for the stock was maintained at $5.50.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 11 ’23 when BOYER ANDREW S sold 29,302 shares for $4.13 per share. The transaction valued at 120,921 led to the insider holds 244,739 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMRX now has a Market Capitalization of 1.64B and an Enterprise Value of 4.35B. As of this moment, Amneal’s Price-to-Earnings (P/E) ratio for their current fiscal year is 83.89, and their Forward P/E ratio for the next fiscal year is 8.30. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.68 while its Price-to-Book (P/B) ratio in mrq is 2.48. Its current Enterprise Value per Revenue stands at 1.82 whereas that against EBITDA is 9.32.
Stock Price History:
Over the past 52 weeks, AMRX has reached a high of $6.30, while it has fallen to a 52-week low of $1.24. The 50-Day Moving Average of the stock is 5.64, while the 200-Day Moving Average is calculated to be 4.20.
Shares Statistics:
For the past three months, AMRX has traded an average of 1.51M shares per day and 1.98M over the past ten days. A total of 151.49M shares are outstanding, with a floating share count of 110.01M. Insiders hold about 64.11% of the company’s shares, while institutions hold 24.79% stake in the company. Shares short for AMRX as of Feb 15, 2024 were 2.1M with a Short Ratio of 1.39, compared to 2.5M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.68% and a Short% of Float of 0.77%.
Earnings Estimates
There are 5 different market analysts currently analyzing its stock. On average, analysts expect EPS of $0.09 for the current quarter, with a high estimate of $0.11 and a low estimate of $0.08, while EPS last year was $0.12. The consensus estimate for the next quarter is $0.14, with high estimates of $0.16 and low estimates of $0.11.
Analysts are recommending an EPS of between $0.63 and $0.53 for the fiscal current year, implying an average EPS of $0.59. EPS for the following year is $0.64, with 5 analysts recommending between $0.7 and $0.54.
Revenue Estimates
A total of 4 analysts believe the company’s revenue will be $612.57M this quarter.It ranges from a high estimate of $631.33M to a low estimate of $589.2M. As of the current estimate, Amneal Pharmaceuticals Inc’s year-ago sales were $557.54M, an estimated increase of 9.90% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $646.09M, an increase of 7.90% less than the figure of $9.90% in the same quarter last year. There is a high estimate of $655M for the next quarter, whereas the lowest estimate is $624.9M.
A total of 5 analysts have provided revenue estimates for AMRX’s current fiscal year. The highest revenue estimate was $2.63B, while the lowest revenue estimate was $2.51B, resulting in an average revenue estimate of $2.59B. In the same quarter a year ago, actual revenue was $2.39B, up 8.20% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $2.68B in the next fiscal year. The high estimate is $2.75B and the low estimate is $2.56B. The average revenue growth estimate for next year is up 3.50% from the average revenue estimate for this year.
